New 3D Printing Research Paves Way for Personalised Medication

-

 


shutterstock_455480596.jpg

A new technique for 3D printing medication has enabled the printing of multiple drugs in a single tablet, paving the way for personalised pills that can deliver timed doses.

Researchers from the University of Nottingham’s, Centre for Additive Manufacturing have led research alongside the School of Pharmacy that has fabricated personalised medicine using Multi-Material InkJet 3D Printing (MM-IJ3DP). The research has been published in Materials Today Advances.

The team have developed a cutting-edge method that enables the fabrication of customised pharmaceutical tablets with tailored drug release profiles, ensuring more precise and effective treatment options for patients.

Using Multi-Material InkJet 3D Printing (MM-IJ3DP), tablets can be printed that release drugs at a controlled rate, determined by the tablet's design.  This is made possible by a novel ink formulation based on molecules that are sensitive to ultraviolet light. When printed, these molecules form a water-soluble structure.

The drug release rate is controlled by the unique interior structure of the tablet, allowing for timing the dosage release. This method can print multiple drugs in a single tablet, allowing for complex medication regimens to be simplified into a single dose.

Dr Yinfeng He, Assistant Professor in the Faculty of Engineering’s Centre for Additive Manufacturing led the research, he said: “This is an exciting step forwards in the development of personalised medication. This breakthrough not only highlights the potential of 3D printing in revolutionising drug delivery but also opens up new avenues for the development of next-generation personalised medicines.”

“While promising, the technology faces challenges, including the need for more formulations that support a wider range of materials. The ongoing research aims to refine these aspects, enhancing the feasibility of MM-IJ3DP for widespread application.” Professor Ricky Wildman added.

This technology will be particularly beneficial in creating medication that needs to release drugs at specific times, making it ideal for treating diseases, where timing and dosage accuracy are crucial. The ability to print 56 pills in a single batch demonstrates the scalability of this technology, providing a strong potential for the production of personalised medicines.

Professor Felicity Rose at the University of Nottingham’s School of Pharmacy was one of the co-authors on the research, she says: “The future of prescribed medication lies in a personalised approach, and we know that up 50% of people in the UK alone don’t take their medicines correctly and this has an impact on poorer health outcomes with conditions not being controlled or properly treated. A single pill approach would simplify taking multiple medications at different times and this research is an exciting step towards that.

Comments

Post a Comment

Popular posts from this blog

Sanofi’s Sarclisa wins in transplant-eligible multiple myeloma trial

-
Image
Sanofi’s Sarclisa (isatuximab) plus standard of care has been shown to extend the time that some multiple myeloma patients remain stable without disease progression. This was demonstrated in a Phase III trial (NCT03617731) with 662 newly diagnosed patients who were eligible for a stem cell transplant. The trial found that adding Sarclisa to the standard drugs – lenalidomide, bortezomib, and dexamethasone (Rvd) – resulted in a statistically significant and clinically meaningful improvement in progression-free survival compared to RVd induction therapy. Sanofi said that these results reinforce the potential of Sarclisa as a backbone therapy when added to the current standard of care in various multiple myeloma patient populations. These recent findings build on data from 2021, where the trial met a different primary endpoint of minimal residual disease (MRD) negativity after induction therapy and before transplant. Around 50.1% of the newly diagnosed multiple myeloma patients achiev...
Read more

MDMA Papers Retracted for ‘Unethical Conduct’ on Heels of Lykos’ FDA Rejection

-
Image
A day after the regulator denied approval of Lykos’ MDMA-assisted PTSD therapy, a medical journal pulled three studies related to the use of the psychedelic in the indication. The medical journal Psychopharmacology on Saturday retracted three papers related to the use of the psychiatric substance MDMA for the treatment of post-traumatic stress disorder. The decision to pull the studies was driven by “protocol violations amounting to unethical conduct” at one of the study sites, according to the journal’s retraction note. The authors of the studies also confirmed to Psychopharmacology that they knew of these breaches when they submitted their manuscript “but did not disclose this information to the journal or remove data generated by this site from their analysis.” Many of the authors failed to fully disclose a “potential competing interest, ” according to the retraction notice, while some of the researchers were affiliated with either the Multidisciplinary Association for Psychedelic...
Read more

Cell and gene therapy companies must demonstrate strong value proposition for investment

-
Image
Investment for companies developing cell and gene therapies (CGTs) was discussed during the GenScript Biotech Global Forum London 2024 conference held on 20 November 2024. Following a sharp drop in CGT investment in 2022, trends suggest that CGT investment is currently undergoing a “renormalisation”. However, investors continue to be selective, said speakers Josh Resnik, senior managing director at RA Capital Management, and Ping Shek, managing director at Stifel’s Healthcare Investment Banking Division. CGTs have faced challenges attracting investment due to the large amount of capital required to manufacture CGTs, as well as hurdles relating to reimbursement of one-off, high-cost therapies and patient access. Resnik noted that investor sentiment about CGTs was impacted by competitive pressures from “not-so-complicated biologics” such as antibody-drug conjugates, radiopharmaceuticals, and T-cell engagers in oncology and immunology. Resnik noted that CGTs must demonstrate a stron...
Read more